Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Fluid biomarkers of immune function in Alzheimer’s disease

Immune system dysregulation is thought to be highly relevant in Alzheimer’s disease (AD), as with most neurodegenerative diseases, and thus efforts to discover and test fluid biomarkers of immune function in AD are underway. The role played by the immune system in AD pathogenesis extends beyond brain-resident immune cells, with research emphasizing the involvement of systemic immune signals. Charlotte Teunissen, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, notes that whilst immune markers lack specificity for AD, they may provide useful prognostic or predictive information. For example, patients with an increased cerebrospinal fluid (CSF) immune biomarker profile have been identified, who may be more likely to benefit from immunotherapy. Network analysis has also found co-expressed protein modules that are strongly associated with long-term dementia risk. Soluble TREM2 changes have been shown to correlate with levels of CSF tau and amyloid, and cortical shrinkage. Additionally, with immune modulation representing a promising therapeutic modality for AD, markers to noninvasively monitor the neuro-immune response will aid in clinical trial conduction. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.


Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND ( IMI 2 Joint Undertaking (JU) under grant agreement No. 101034344grant no) and JPND (bPRIDE), National MS Society (Progressive MS alliance) and Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds.
CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. She had speaker contracts for Roche, Grifols, Novo Nordisk.